Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
Design and screening of a glial cell-specific, cell penetrating Peptide for therapeutic applications in multiple sclerosis.
Chronic inflammatory demyelinating polyneuropathy following malignant melanoma.
Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
Receptos provides update on progress of lead product candidate RPC1063
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.
3D models of human ERα and ERβ complexed with coumestrol.
Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.
Treatment selection and experience in multiple sclerosis: survey of neurologists.
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis
CLARITY – Safety and Efficacy of Oral Cladribine in Subjects with Relapsing-remitting Multiple Sclerosis (MS)
[Epidemiology of multiple sclerosis in the Primosky Krai and Far East regions.]
Physiopathology of symptoms and signs in multiple sclerosis.
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
SMC Says Yes to Lemtrada(R)a- 1/4 (alemtuzumab) 12mg IV, a New Treatment for Adults with Active Relapsing Remitting-Multiple Sclerosis (RRMS)
Parent-of-origin effect in multiple sclerosis: observations in half-siblings.
The risk of multiple sclerosis in bereaved parents: A nationwide cohort study in Denmark.
Medicare Part D payments for neurologist-prescribed drugs.
Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.
Central motor conduction time may predict response to fampridine in patients with multiple sclerosis.
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Normal outcome of pregnancy with ongoing treatment with natalizumab.
Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
Involvement of oxidative stress on the impairment of energy metabolism induced by A beta peptides on PC12 cells: protection by antioxidants.
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.

Pages